These restrictions on disclosure will apply equally to all future information supplied to you, which is indicated as privileged or confidential. This material may be disclosed to and used by your staff and associates as may be necessary to conduct this clinical study. STATISTICAL ANALYSIS PLAN PROTOCOL TITLE: A Multi -Center Phase III, Randomized, Open -Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing’s Sarcoma PROTOCOL NUMBER: CL-PTL-130 STUDY AGENT(S): Vigil bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy SPONSOR: Gradalis, Inc. 2545 Golden Bear Drive, Suite 110 Carrollton, TX 75006 Phone: (214) 442-8124 Fax: (214) 442-8101 Statistical Analysis Plan IND 014205 Ph III Ewing’s Sarcoma Vigil ± Irinotecan +Temozolomide CL-SAP-00001 Version: 03 Page 2 of 19 Confidential and proprietary information of Gradalis, Inc. Effective: 05-DEC-2018 It is the user’s responsibility to verify adequate training before executing a document.